DGAP-Adhoc

Cytos Biotechnology AG exclusively licenses its VLP platform for the treatment of hepatitis B infections to OnCore Biopharma - Seite 2

for Disease Control and Prevention (CDC) indicate that up to 350 million
people globally may be chronically infected with hepatitis B and, according
to the World Health Organization (WHO), more than 780,000 people die every
year due to hepatitis B. Most currently-available therapies aim to suppress
this viral infection but do not lead to a cure in the overwhelming majority
of patients.


About Cytos Biotechnology Ltd

Cytos is a public biopharmaceutical company located in Schlieren (Zurich),
Switzerland. The Company is listed according to the Main Standard on the
SIX Swiss Exchange Ltd under the symbol CYTN.


About Cytos' VLP platform
Cytos proprietory, versatile and highly-defined VLP platform which can be
used for the generation B- and T- cell vaccines and as immunmodulators is
based on bacteriophage Q beta-derived virus-like particles (Qb VLPs). These
QbVLPs act as immune-stimulatory carriers for disease-associated antigens
and can be used for the delivery of immune modulators. The platform builds
on the repetitive and highly ordered protein array formed by Qb VLPs and
the immune stimulatory nucleic acids included inside the VLPs acting as
toll-like receptor (TLR) - ligands. GMP grade Qb VLPs are produced
efficiently at large scale in E.coli. Qb VLPs can either be used directly
as immune stimulators, or combined with selected antigens chemically linked
to the VLP surface as conjugate vaccine.

Cytos and its partners have tested a wide array of antigens ranging from
chemical entities, to peptides, to large multimeric proteins. Vaccine
candidates based on Cytos' Qb VLP platform have been tested in various
preclinical and clinical studies and were found to be safe, generally well
tolerated and highly immunogenic. The vaccine platform is modular, robust
and scalable. Clinical programs include the partnered B-cell vaccine
programs against Alzheimer's Disease with Novartis, against allergy with
Pfizer and against influenza with A*Star. Moreover the QbVLPs filled with a
TLR9 agonist were clinically tested for a T-cell vaccine candidate against
Melanoma as well as an immune modulator in allergic diseases like rhinitis
and allergic asthma.

Forward Looking Statements
This media release contains certain forward-looking statements that involve
risks and uncertainties that could cause actual results to be materially
different from historical results or from any future results expressed or
implied by such forward-looking statements. You are urged to consider
statements that include the words "will" or "expect" or the negative of
those words or other similar words to be uncertain and forward-looking.